Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.2 , No. 5, Publication Date: Sep. 22, 2015, Page: 50-59
 are generally not treated although a significant proportion (about 1/3) progress to T2DM and they are associated with increased cardiovascular morbidity. Pre-diabetes can be reverted to normal much easier than diabetes. Our study proposes a novel way of assessing the pre-diabetic and diabetic states via oral glucose tolerance test – OGTT – and a new metric calculated from its 3 data points: the glucose metabolic index or GMI. Inferences about insulin secretion and sensitivity can be made accurately using GMI, which can be a very useful tool in guiding therapy in both new and established patients with diabetes and offers more prompt and ample information than the measurement of glycated hemoglobin.&picture=http://www.aascit.org/aascit/decorators/img/journal/972.jpg)
| [1] | Felician Stancioiu, Department of Medicine and Medical Research, the Bio-Forum Foundation, Bucharest, Romania. |
| [2] | T. McKenzie, Department of Medicine and Medical Research, the Bio-Forum Foundation, Bucharest, Romania. |
| [3] | M. Rodriguez, Department of Medicine and Medical Research, the Bio-Forum Foundation, Bucharest, Romania. |
| [4] | S. Ahmed, Department of Medicine and Medical Research, the Bio-Forum Foundation, Bucharest, Romania. |
Diabetes in its various forms is a global health problem and contributes directly and indirectly to a significant portion of healthcare expenses. 90% or more of diabetes cases are of the insulin-resistance variety and there is no known cure for the well-established type 2 diabetes except for cases of spontaneous remission after bariatric surgery. Pre-diabetic states (impaired glucose tolerance, IGT and impaired fasting glucose, IFG) are generally not treated although a significant proportion (about 1/3) progress to T2DM and they are associated with increased cardiovascular morbidity. Pre-diabetes can be reverted to normal much easier than diabetes. Our study proposes a novel way of assessing the pre-diabetic and diabetic states via oral glucose tolerance test – OGTT – and a new metric calculated from its 3 data points: the glucose metabolic index or GMI. Inferences about insulin secretion and sensitivity can be made accurately using GMI, which can be a very useful tool in guiding therapy in both new and established patients with diabetes and offers more prompt and ample information than the measurement of glycated hemoglobin.
Keywords
Insulin Resistance, Pre-Diabetes, Diabetes, Oral Glucose Tolerance Test, OGTT, Glucose Metabolic Index, GMI, Insulin for Type 2 Diabetes
Reference
| [01] | Shaw JE, Zimmet PZ, McCarty D, Courten MD. Type 2 diabetes worldwide according to the new classification and criteria. Diabetes Care. 2000; 23, Suppl 2, B5-B10. |
| [02] | Carter JS, Pugh JA, Monterrosa A. Non-Insulin-Dependent Diabetes Mellitus in Minorities in the United States. Annals of Internal Medicine. 1996; 125(3):221-232. |
| [03] | Lee ET, Howard BV, Savage PJ, et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45-74 years. The Strong Heart Study. Diabetes Care. 1995; 18 (5): 599-610. |
| [04] | Foster D W. Diabetes Mellitus. In: Fauci A S, Braunwald E, Isselbacher K J, ed. Harrison’s Principles of Internal Medicine. 14 th ed. McGraw-Hill; 1998: 2060-2081. |
| [05] | Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes. Endocrine Reviews. 2002; 23(5):599-622. |
| [06] | Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care. 2003; 26(11):3160-67. |
| [07] | Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002; 19(9):708-23. |
| [08] | Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393-403. |
| [09] | Lindstrom J, Eriksson JG, Valle TT, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. J Am Soc Nephrol. 2003; 14 (7 Suppl 2): S108-13. |
| [10] | Chiasson JL, Josse G, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002; 359 (9323): 2072-7. |
| [11] | Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3):725-31. |
| [12] | Thamer C, Haap M, Heller E, et al. Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res. 2006; 38(3):178-82. |
| [13] | Gunczler P, Lanes R. Reelationship between different fasting-based insulin sensitivity indices in obese children and adolescents. Journal of Pediatrics Endocrinology and Metabolism. 2006; 19(3):259-65. |
| [14] | Bravata DM, Wells CK, Concato J, et al. Two measures of insulin sensitivity provided similar information in a US population. Journal of Clinical Epidemiology. 2004; 57(11):1214-7. |
| [15] | Schnell O, Standl E. Impaired glucose tolerance, diabetes and cardiovascular disease. Endocr Pract. 2006; 12 (Suppl 1):16-19. |
| [16] | Santos JF, Almeida M, Ferreira J, et al. Glucose metabolism in non-diabetic patients with stable coronary artery disease. Rev Port Cardiol. 2006; 25(1):39-53. |
| [17] | Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. Journal of Clinical Investigations. 1981; 68(6):1456-67. |
| [18] | Zheng Y, Zhao M. Modified minimal model using a single-step fitting process for the intravenous glucose tolerance test in Type 2 diabetes and healthy humans. Comput Methods Programs Biomed. 2005; 79 (1): 73-9. |
| [19] | Thomaseth K, Kautzky-Willer A, Ludvik B, et al. Integrated mathematical model to assess beta-cell activity during the oral glucose test. Am J Physiol. 1996; 270(3 Pt 1): E522-31. |
| [20] | Andersen KE, Hojbjerre M. A population-based Bayesian approach to the minimal model of glucose and insulin homeostasis. Stat Med. 2005; 24(15):2381-400. |
| [21] | Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. J Clin Endocrinol Metab. 2000; 85:4396-4402. |
| [22] | Man CD, Campioni M, Polonsky KS, et al. Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol: Minimal Model Assesment of beta-Cell Responsivity and Insulin Sensitivity in Nondiabetic Individuals. Diabetes. 2005; 54(11):3265-73. |
| [23] | Cretti A, Brunato B, Zenti MG, et al. A novel tool to assess Beta-cell function during the oral glucose tolerance test (OGTT). Diabetes. 2000; 49 (Suppl 1): A89. |
| [24] | Magni P, Sparacino G, Bellazzi R et al. Reduced Sampling Schedule for the Glucose Minimal Model: Importance of Bayesian Estimation. Am J Physiol Endocrinol Metab. 2005; Sep 6 (Epub ahead of print). |
| [25] | Mari A, Pacini G, Brazzale AR, Ahren B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia. 2005; 48(4):748-51. |
| [26] | Mari A, Ahren B, Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care. 2005; 8(5):529-33. |
| [27] | Tura A, Ludvik B, Nolan JJ, et al. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab. 2001; 281(5); E966-74. |
| [28] | Man CD, Yarasheski KE, Caumo A et al. Insulin sensitivity by oral glucose minimal models: validation against clamp. American Journal of Physiology Endocrinology and metabolism. 2005; 289(6): E954-9. |
| [29] | Breda E, Cavaghan MK, Toffolo G, et al. Oral Glucose Tolerance Test Minimal Models Indexes of Beta-Cell Function and Insulin Sensitivity. Diabetes. 2001; 50:150-8. |
| [30] | Stancioiu F, Ahmed S. Helicobacter pylori: findings in a Native American population. IHS Primary Care Provider. March 2005. |
| [31] | Ibanez J, Izquierdo M, Arguelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care. 2005; 28 (3): 662-7. |
| [32] | Hayashi Y, Nagasaka S, Takahashi N, et al. A singlebout of exercise at higher intensity enhances glucose effectiveness in sedentary men. J Clin Endocrinol Metab. 2005; 90(7):4035-40. |
| [33] | Thompson WG, Slezak JM. Correlations between measures of insulin sensitivity and weight loss. Diabetes Res Clin Pract. 2006; Apr 17 – Epub ahead of print. |
| [34] | Bhoraskar A. Nutrition in prediabetes. J Indian Med Assoc. 2005; 103(11):596-99. |
| [35] | Stancioiu F. Effect of fatty acids and antioxidants on glucose tolerance Acta Endo (Buc) 2007 3: 391-404. |
| [36] | Kopprasch S, Pietzsch J, Kuhlisch E, et al. In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance. Diabetes. 2002; 51 (10): 3102-3106. |
| [37] | Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies in Patients with Type 2 Diabetes Mellitus. Ann NY Acad Sci. 2005; 1051:97-103 |
| [38] | Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 1994; 43:1010-14 |
| [39] | Phillips C, Owens D, Collins P, Tomkin GH. Low density lipoprotein non-esterified fatty acids and lipoprotein lipase in diabetes. Atherosclerosis. 2005; 181:109-14. |
| [40] | Salsbury CG: Disease incidence among the Navajos. Southwest Med. 1937; 21: 230-233. |
| [41] | Ravussin E, Valencia ME, Esparza J, et al. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care. 1994; 17:1067-74. |
| [42] | Li L, Sawamura T, Renier G. Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes. 2003; 52 (7): 1843-50. |
| [43] | Staprans I, Hardman DA, Pan XM, Feingold KR. Effect of oxidized lipids in the diet on oxidized lipid levels in postprandial serum chylomicrons of diabetic patients. Diabetes Care. 1999; 22 (2): 300-306. |
| [44] | Sawamura T. LOX-1 Unlocked. Structure. 2005; 13: 834-5. |
| [45] | Bruun JM, Nielsen CB, Pedersen SB, et al. Estrogen Reduces Pro-Inflammatory Cytokines in Rodent Adipose Tissue: Studies in vivo and in vitro. Horm Metab Res. 2003; 35(3):142-6. |
| [46] | Kuhn H, O’Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Progress in Lipid Research. 2006; 45(4):334-356. |
| [47] | Chung S, Brown JM, Provo JN, et al. Conjugated Linoleic Acid Promotes Human Adipocyte Insulin Resistance through NF (kappa)B-dependent Cytokine Production. J Biol Chem. 2005; 280(46):38445-56 |
| [48] | Suzawa M, Takada I, Yanagisawa J, et al. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol. 2003; 5(3):224-30. |
| [49] | de Negris F, Gallo L, Sica V, Napoli C. Glycoxidation of low-density lipoprotein promotes multiple apoptotic pathways and N Fkappa B activation in human coronary cells. Basic Res Cardiol. 2006; 101:101-8. |
| [50] | Ortis F, Cardozo AK, Crispim D, et al. Cytokine-induced pro-apoptotic gene expression in insulin-producing cells is related to rapid, sustained and non-oscillatory NF-kappa B activation. Mol Endocrinol. 2006; March 23- Epub ahead of print. |
| [51] | Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23:599-622. |
